<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00725621</url>
  </required_header>
  <id_info>
    <org_study_id>P03756</org_study_id>
    <nct_id>NCT00725621</nct_id>
  </id_info>
  <brief_title>Real Life Dosing of Remicade for Rheumatoid Arthritis in Austria Monitored Over 9 Infusions (Study P03756)(COMPLETED)</brief_title>
  <official_title>Real Life Dosing Regimen of Remicade in Austria, Monitored Over 9 Consecutive Infusions in Rheumatoid Arthritis Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centocor, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open-label, 1-arm, multicenter observational study to determine the
      average Remicade dosage and time span between 9 infusions in subjects with rheumatoid
      arthritis (RA)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study population was chosen from a non-probability sample.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Time Interval Between Remicade Infusions in Participants During Maintenance Treatment Following Induction Therapy</measure>
    <time_frame>Maximum of 16 weeks</time_frame>
    <description>The impact of the maintenance therapy location (specialized hospitals versus extramural infusion centers) was also examined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Time Interval Between Remicade Infusions in Participants During Maintenance Treatment Following Induction Therapy</measure>
    <time_frame>Maximum of 16 weeks</time_frame>
    <description>The impact of the maintenance therapy location (specialized hospitals versus extramural infusion centers) was also examined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Dose of Remicade in Participants Receiving Induction Therapy and Subsequent Maintenance Therapy</measure>
    <time_frame>Maximum of 102 weeks</time_frame>
    <description>The impact of the maintenance therapy location (specialized hospitals versus extramural infusion centers) was also examined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Dose of Remicade in Participants Receiving Induction Therapy and Subsequent Maintenance Therapy</measure>
    <time_frame>Maximum of 102 weeks</time_frame>
    <description>The impact of the maintenance therapy location (specialized hospitals versus extramural infusion centers) was also examined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Remicade Dose Per Participant</measure>
    <time_frame>Maximum of 102 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Remicade Dose Per Participant</measure>
    <time_frame>Maximum of 102 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Progression Specified by the Time Period Between Onset of Rheumatoid Arthritis (RA) and Onset of Remicade Therapy</measure>
    <time_frame>24 months maximum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Kind of Previous Therapies With Disease-Modifying Anti-Rheumatic Drugs (DMARDs)</measure>
    <time_frame>24 months maximum</time_frame>
    <description>Some participants had more than one previous treatment with a DMARD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Remicade Location (Specialized Hospitals Versus Extramural Infusion Centers) on the Physical Component Summary Score (PCS)</measure>
    <time_frame>24 months maximum</time_frame>
    <description>Participant's quality of life was measured by the short-form 36 (SF-36). The SF-36 is a survey with 36 questions. It is composed of the PCS &amp; the Mental Component Summary Score (MCS). The SF-36 consisted of eight scaled scores, which were the weighted sums of the questions in their section. Each scale was directly transformed into a 0 (lowest level of functioning) - 100 (highest level of functioning) scale on the assumption that each question carried equal weight. The impact of the maintenance therapy location (specialized hospitals versus extramural infusion centers) was also examined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Remicade Location (Specialized Hospitals Versus Extramural Infusion Centers) on the MCS</measure>
    <time_frame>24 months maximum</time_frame>
    <description>Participant's quality of life was measured by the short-form 36 (SF-36). The SF-36 is a survey with 36 questions. It is composed of the PCS &amp; the MCS. The SF-36 consisted of eight scaled scores, which were the weighted sums of the questions in their section. Each scale was directly transformed into a 0 (lowest level of functioning) - 100 (highest level of functioning) scale on the assumption that each question carried equal weight. The impact of the maintenance therapy location (specialized hospitals versus extramural infusion centers) was also examined.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">516</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Remicade</arm_group_label>
    <description>Patients with severe RA (indication according to Austrian labeling) will receive Remicade induction therapy consisting of three Remicade infusions in weeks 0, 2, and 6 given in specialized centers. Maintenance therapy will consist of another maximal 6 infusions. Remicade induction and maintenance therapy doses and intervals will be at the discretion of the physicians.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>Remicade induction therapy consisting of three Remicade infusions in weeks 0, 2, and 6 given in specialized centers. Maintenance therapy will consist of another maximal 6 infusions given in doses and intervals due to discretion of physicians.</description>
    <arm_group_label>Remicade</arm_group_label>
    <other_name>Remicade</other_name>
    <other_name>SCH 215596</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with severe RA being treated at specialized centers.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe RA (indication according to Austrian labeling).

        Exclusion Criteria:

          -  According to Summary of Product Characteristics (SPC).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Austria</country>
  </removed_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2008</study_first_submitted>
  <study_first_submitted_qc>July 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2008</study_first_posted>
  <results_first_submitted>July 8, 2011</results_first_submitted>
  <results_first_submitted_qc>July 8, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 4, 2011</results_first_posted>
  <last_update_submitted>September 2, 2015</last_update_submitted>
  <last_update_submitted_qc>September 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Remicade (Specialized Hospitals &amp; Extramural Infusion Centers)</title>
          <description>Remicade induction therapy consisted of 3 infusions (3 mg/kg) in weeks 0, 2, and 6 given in specialized centers (specialized hospitals and extramural infusion centers). Maintenance therapy consisted of a maximum of 6 infusions (3 mg/kg) given in doses and intervals at the discretion of physician. The observation period could not exceed 102 weeks per participant if the maximal therapy interval of 16 weeks as defined in Summary of Product Characteristics (SPC) was taken into consideration.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="516">Started was defined as the number of participants who received at least one infusion of Remicade.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="245">Completed was defined as the number of participants who received 9 consecutive Remicade infusions.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="271"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Continued treatment by other physician</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Switched to other study</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Switched to other drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Prepared for elective surgery</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not specified</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Remicade (Specialized Hospitals &amp; Extramural Infusion Centers)</title>
          <description>Remicade induction therapy consisted of 3 infusions (3 mg/kg) in weeks 0, 2, and 6 given in specialized centers (specialized hospitals and extramural infusion centers). Maintenance therapy consisted of a maximum of 6 infusions (3 mg/kg) given in doses and intervals at the discretion of physician. The observation period could not exceed 102 weeks per participant if the maximal therapy interval of 16 weeks as defined in SPC was taken into consideration.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="516"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.43" spread="13.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Time Interval Between Remicade Infusions in Participants During Maintenance Treatment Following Induction Therapy</title>
        <description>The impact of the maintenance therapy location (specialized hospitals versus extramural infusion centers) was also examined.</description>
        <time_frame>Maximum of 16 weeks</time_frame>
        <population>Remicade-naive participants who received Remicade induction therapy and subsequent maintenance therapy during the observational study.</population>
        <group_list>
          <group group_id="O1">
            <title>Remicade (Specialized Hospitals &amp; Extramural Infusion Centers)</title>
            <description>Remicade induction therapy consisted of 3 infusions (3 mg/kg) in weeks 0, 2, and 6 given in specialized centers (specialized hospitals and extramural infusion centers). Maintenance therapy consisted of a maximum of 6 infusions (3 mg/kg) given in doses and intervals at the discretion of physician. The observation period could not exceed 102 weeks per participant if the maximal therapy interval of 16 weeks as defined in SPC was taken into consideration.</description>
          </group>
          <group group_id="O2">
            <title>Remicade (Specialized Hospitals Only)</title>
            <description>Remicade induction therapy consisted of 3 infusions (3 mg/kg) in weeks 0, 2, and 6 given in specialized hospitals. Maintenance therapy consisted of a maximum of 6 infusions (3 mg/kg) given in doses and intervals at the discretion of physician. The observation period could not exceed 102 weeks per participant if the maximal therapy interval of 16 weeks as defined in SPC was taken into consideration.</description>
          </group>
          <group group_id="O3">
            <title>Remicade (Extramural Infusion Centers Only)</title>
            <description>Remicade induction therapy consisted of 3 infusions (3 mg/kg) in weeks 0, 2, and 6 given in extramural infusion centers. Maintenance therapy consisted of a maximum of 6 infusions (3 mg/kg) given in doses and intervals at the discretion of physician. The observation period could not exceed 102 weeks per participant if the maximal therapy interval of 16 weeks as defined in SPC was taken into consideration.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Time Interval Between Remicade Infusions in Participants During Maintenance Treatment Following Induction Therapy</title>
          <description>The impact of the maintenance therapy location (specialized hospitals versus extramural infusion centers) was also examined.</description>
          <population>Remicade-naive participants who received Remicade induction therapy and subsequent maintenance therapy during the observational study.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infusion 3/4 (n=193, n=120, n=73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.48" spread="10.94"/>
                    <measurement group_id="O2" value="56.32" spread="7.76"/>
                    <measurement group_id="O3" value="56.75" spread="14.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 4/5 (n=193, n=120, n=73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.55" spread="10.81"/>
                    <measurement group_id="O2" value="56.83" spread="10.66"/>
                    <measurement group_id="O3" value="58.73" spread="11.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 5/6 (n=178, n=110, n=68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.80" spread="10.85"/>
                    <measurement group_id="O2" value="56.60" spread="13.07"/>
                    <measurement group_id="O3" value="57.13" spread="5.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 6/7 (n=163, n=99, n=64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.07" spread="8.57"/>
                    <measurement group_id="O2" value="55.41" spread="8.56"/>
                    <measurement group_id="O3" value="57.09" spread="8.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 7/8 (n=153, n=91, n=62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.33" spread="10.97"/>
                    <measurement group_id="O2" value="56.43" spread="12.11"/>
                    <measurement group_id="O3" value="58.65" spread="8.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 8/9 (n=143, n=83, n=60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.04" spread="11.07"/>
                    <measurement group_id="O2" value="56.60" spread="12.49"/>
                    <measurement group_id="O3" value="57.65" spread="8.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Time Interval Between Remicade Infusions in Participants During Maintenance Treatment Following Induction Therapy</title>
        <description>The impact of the maintenance therapy location (specialized hospitals versus extramural infusion centers) was also examined.</description>
        <time_frame>Maximum of 16 weeks</time_frame>
        <population>Remicade-naive participants who received Remicade induction therapy and subsequent maintenance therapy during the observational study.</population>
        <group_list>
          <group group_id="O1">
            <title>Remicade (Specialized Hospitals &amp; Extramural Infusion Centers)</title>
            <description>Remicade induction therapy consisted of 3 infusions (3 mg/kg) in weeks 0, 2, and 6 given in specialized centers (specialized hospitals and extramural infusion centers). Maintenance therapy consisted of a maximum of 6 infusions (3 mg/kg) given in doses and intervals at the discretion of physician. The observation period could not exceed 102 weeks per participant if the maximal therapy interval of 16 weeks as defined in SPC was taken into consideration.</description>
          </group>
          <group group_id="O2">
            <title>Remicade (Specialized Hospitals Only)</title>
            <description>Remicade induction therapy consisted of 3 infusions (3 mg/kg) in weeks 0, 2, and 6 given in specialized hospitals. Maintenance therapy consisted of a maximum of 6 infusions (3 mg/kg) given in doses and intervals at the discretion of physician. The observation period could not exceed 102 weeks per participant if the maximal therapy interval of 16 weeks as defined in SPC was taken into consideration.</description>
          </group>
          <group group_id="O3">
            <title>Remicade (Extramural Infusion Centers Only)</title>
            <description>Remicade induction therapy consisted of 3 infusions (3 mg/kg) in weeks 0, 2, and 6 given in extramural infusion centers. Maintenance therapy consisted of a maximum of 6 infusions (3 mg/kg) given in doses and intervals at the discretion of physician. The observation period could not exceed 102 weeks per participant if the maximal therapy interval of 16 weeks as defined in SPC was taken into consideration.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time Interval Between Remicade Infusions in Participants During Maintenance Treatment Following Induction Therapy</title>
          <description>The impact of the maintenance therapy location (specialized hospitals versus extramural infusion centers) was also examined.</description>
          <population>Remicade-naive participants who received Remicade induction therapy and subsequent maintenance therapy during the observational study.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infusion 3/4 (n=193, n=120, n=73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.00" lower_limit="25.00" upper_limit="135.00"/>
                    <measurement group_id="O2" value="57.00" lower_limit="29.00" upper_limit="85.00"/>
                    <measurement group_id="O3" value="57.00" lower_limit="25.00" upper_limit="135.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 4/5 (n=193, n=120, n=73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.00" lower_limit="41.00" upper_limit="120.00"/>
                    <measurement group_id="O2" value="57.00" lower_limit="41.00" upper_limit="116.00"/>
                    <measurement group_id="O3" value="57.00" lower_limit="43.00" upper_limit="120.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 5/6 (n=178, n=110, n=68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.00" lower_limit="30.00" upper_limit="140.00"/>
                    <measurement group_id="O2" value="57.00" lower_limit="30.00" upper_limit="140.00"/>
                    <measurement group_id="O3" value="57.00" lower_limit="42.00" upper_limit="71.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 6/7 (n=163, n=99, n-64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.00" lower_limit="30.00" upper_limit="106.00"/>
                    <measurement group_id="O2" value="57.00" lower_limit="41.00" upper_limit="92.00"/>
                    <measurement group_id="O3" value="57.00" lower_limit="30.00" upper_limit="106.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 7/8 (n=153, n=91, n=62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.00" lower_limit="13.00" upper_limit="112.00"/>
                    <measurement group_id="O2" value="57.00" lower_limit="13.00" upper_limit="97.00"/>
                    <measurement group_id="O3" value="57.00" lower_limit="44.00" upper_limit="112.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 8/9 (n=143, n=83, n=60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.00" lower_limit="24.00" upper_limit="113.00"/>
                    <measurement group_id="O2" value="57.00" lower_limit="24.00" upper_limit="113.00"/>
                    <measurement group_id="O3" value="57.00" lower_limit="43.00" upper_limit="111.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Dose of Remicade in Participants Receiving Induction Therapy and Subsequent Maintenance Therapy</title>
        <description>The impact of the maintenance therapy location (specialized hospitals versus extramural infusion centers) was also examined.</description>
        <time_frame>Maximum of 102 weeks</time_frame>
        <population>Remicade-naive participants who received Remicade induction therapy and subsequent maintenance therapy during the observational study.</population>
        <group_list>
          <group group_id="O1">
            <title>Remicade (Specialized Hospitals &amp; Extramural Infusion Centers)</title>
            <description>Remicade induction therapy consisted of 3 infusions (3 mg/kg) in weeks 0, 2, and 6 given in specialized centers (specialized hospitals and extramural infusion centers). Maintenance therapy consisted of a maximum of 6 infusions (3 mg/kg) given in doses and intervals at the discretion of physician. The observation period could not exceed 102 weeks per participant if the maximal therapy interval of 16 weeks as defined in SPC was taken into consideration.</description>
          </group>
          <group group_id="O2">
            <title>Remicade (Specialized Hospitals Only)</title>
            <description>Remicade induction therapy consisted of 3 infusions (3 mg/kg) in weeks 0, 2, and 6 given in specialized hospitals. Maintenance therapy consisted of a maximum of 6 infusions (3 mg/kg) given in doses and intervals at the discretion of physician. The observation period could not exceed 102 weeks per participant if the maximal therapy interval of 16 weeks as defined in SPC was taken into consideration.</description>
          </group>
          <group group_id="O3">
            <title>Remicade (Extramural Infusion Centers Only)</title>
            <description>Remicade induction therapy consisted of 3 infusions (3 mg/kg) in weeks 0, 2, and 6 given in extramural infusion centers. Maintenance therapy consisted of a maximum of 6 infusions (3 mg/kg) given in doses and intervals at the discretion of physician. The observation period could not exceed 102 weeks per participant if the maximal therapy interval of 16 weeks as defined in SPC was taken into consideration.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Dose of Remicade in Participants Receiving Induction Therapy and Subsequent Maintenance Therapy</title>
          <description>The impact of the maintenance therapy location (specialized hospitals versus extramural infusion centers) was also examined.</description>
          <population>Remicade-naive participants who received Remicade induction therapy and subsequent maintenance therapy during the observational study.</population>
          <units>milligrams/kilograms (mg/kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infusion 1 (n=193, n=120, n=73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.42" spread="0.59"/>
                    <measurement group_id="O2" value="3.50" spread="0.59"/>
                    <measurement group_id="O3" value="3.30" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 2 (n=192, n=119, n=73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.43" spread="0.59"/>
                    <measurement group_id="O2" value="3.51" spread="0.59"/>
                    <measurement group_id="O3" value="3.31" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 3 (n=193, n=120, n=73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.46" spread="0.62"/>
                    <measurement group_id="O2" value="3.56" spread="0.65"/>
                    <measurement group_id="O3" value="3.30" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 4 (n=193, n=120, n=73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.50" spread="0.62"/>
                    <measurement group_id="O2" value="3.59" spread="0.63"/>
                    <measurement group_id="O3" value="3.36" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 5 (n=193, n=120, n=73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.53" spread="0.67"/>
                    <measurement group_id="O2" value="3.62" spread="0.71"/>
                    <measurement group_id="O3" value="3.36" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 6 (n=178, n=110, n=68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.56" spread="0.70"/>
                    <measurement group_id="O2" value="3.70" spread="0.75"/>
                    <measurement group_id="O3" value="3.34" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 7 (n=163, n=99, n=64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.63" spread="0.74"/>
                    <measurement group_id="O2" value="3.78" spread="0.82"/>
                    <measurement group_id="O3" value="3.39" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 8 (n=153, n=91, n=62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.60" spread="0.72"/>
                    <measurement group_id="O2" value="3.75" spread="0.79"/>
                    <measurement group_id="O3" value="3.37" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 9 (n=143, n=83, n=60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.61" spread="0.72"/>
                    <measurement group_id="O2" value="3.79" spread="0.78"/>
                    <measurement group_id="O3" value="3.36" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Progression Specified by the Time Period Between Onset of Rheumatoid Arthritis (RA) and Onset of Remicade Therapy</title>
        <time_frame>24 months maximum</time_frame>
        <population>Remicade-naive participants who were exposed to Remicade during the observational study.</population>
        <group_list>
          <group group_id="O1">
            <title>Remicade (Specialized Hospitals &amp; Extramural Infusion Centers)</title>
            <description>Remicade induction therapy consisted of 3 infusions (3 mg/kg) in weeks 0, 2, and 6 given in specialized centers (specialized hospitals and extramural infusion centers). Maintenance therapy consisted of a maximum of 6 infusions (3 mg/kg) given in doses and intervals at the discretion of physician. The observation period could not exceed 102 weeks per participant if the maximal therapy interval of 16 weeks as defined in SPC was taken into consideration.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Progression Specified by the Time Period Between Onset of Rheumatoid Arthritis (RA) and Onset of Remicade Therapy</title>
          <population>Remicade-naive participants who were exposed to Remicade during the observational study.</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="511"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.02" spread="8.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Kind of Previous Therapies With Disease-Modifying Anti-Rheumatic Drugs (DMARDs)</title>
        <description>Some participants had more than one previous treatment with a DMARD.</description>
        <time_frame>24 months maximum</time_frame>
        <population>Remicade-naive participants who were exposed to Remicade during the observational study.</population>
        <group_list>
          <group group_id="O1">
            <title>Remicade (Specialized Hospitals &amp; Extramural Infusion Centers)</title>
            <description>Remicade induction therapy consisted of 3 infusions (3 mg/kg) in weeks 0, 2, and 6 given in specialized centers (specialized hospitals and extramural infusion centers). Maintenance therapy consisted of a maximum of 6 infusions (3 mg/kg) given in doses and intervals at the discretion of physician. The observation period could not exceed 102 weeks per participant if the maximal therapy interval of 16 weeks as defined in SPC was taken into consideration.</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Kind of Previous Therapies With Disease-Modifying Anti-Rheumatic Drugs (DMARDs)</title>
          <description>Some participants had more than one previous treatment with a DMARD.</description>
          <population>Remicade-naive participants who were exposed to Remicade during the observational study.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="516"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Methotrexate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sulfasalazine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leflunomide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Dose of Remicade in Participants Receiving Induction Therapy and Subsequent Maintenance Therapy</title>
        <description>The impact of the maintenance therapy location (specialized hospitals versus extramural infusion centers) was also examined.</description>
        <time_frame>Maximum of 102 weeks</time_frame>
        <population>Remicade-naive participants who received Remicade induction therapy and subsequent maintenance therapy during the observational study.</population>
        <group_list>
          <group group_id="O1">
            <title>Remicade (Specialized Hospitals &amp; Extramural Infusion Centers)</title>
            <description>Remicade induction therapy consisted of 3 infusions (3 mg/kg) in weeks 0, 2, and 6 given in specialized centers (specialized hospitals and extramural infusion centers). Maintenance therapy consisted of a maximum of 6 infusions (3 mg/kg) given in doses and intervals at the discretion of physician. The observation period could not exceed 102 weeks per participant if the maximal therapy interval of 16 weeks as defined in SPC was taken into consideration.</description>
          </group>
          <group group_id="O2">
            <title>Remicade (Specialized Hospitals Only)</title>
            <description>Remicade induction therapy consisted of 3 infusions (3 mg/kg) in weeks 0, 2, and 6 given in specialized hospitals. Maintenance therapy consisted of a maximum of 6 infusions (3 mg/kg) given in doses and intervals at the discretion of physician. The observation period could not exceed 102 weeks per participant if the maximal therapy interval of 16 weeks as defined in SPC was taken into consideration.</description>
          </group>
          <group group_id="O3">
            <title>Remicade (Extramural Infusion Centers Only)</title>
            <description>Remicade induction therapy consisted of 3 infusions (3 mg/kg) in weeks 0, 2, and 6 given in extramural infusion centers. Maintenance therapy consisted of a maximum of 6 infusions (3 mg/kg) given in doses and intervals at the discretion of physician. The observation period could not exceed 102 weeks per participant if the maximal therapy interval of 16 weeks as defined in SPC was taken into consideration.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Dose of Remicade in Participants Receiving Induction Therapy and Subsequent Maintenance Therapy</title>
          <description>The impact of the maintenance therapy location (specialized hospitals versus extramural infusion centers) was also examined.</description>
          <population>Remicade-naive participants who received Remicade induction therapy and subsequent maintenance therapy during the observational study.</population>
          <units>mg/kg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="120"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Infusion 1 (n=193, n=120, n=73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.33" lower_limit="2.25" upper_limit="6.15"/>
                    <measurement group_id="O2" value="3.38" lower_limit="2.45" upper_limit="5.97"/>
                    <measurement group_id="O3" value="3.23" lower_limit="2.25" upper_limit="6.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 2 (n=192, n=119, n=73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.33" lower_limit="2.25" upper_limit="6.15"/>
                    <measurement group_id="O2" value="3.39" lower_limit="2.56" upper_limit="5.97"/>
                    <measurement group_id="O3" value="3.23" lower_limit="2.25" upper_limit="6.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 3 (n=193, n=120, n=73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.33" lower_limit="2.22" upper_limit="5.97"/>
                    <measurement group_id="O2" value="3.40" lower_limit="2.22" upper_limit="5.88"/>
                    <measurement group_id="O3" value="3.23" lower_limit="2.41" upper_limit="5.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 4 (n=193, n=120, n=73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.41" lower_limit="2.44" upper_limit="5.80"/>
                    <measurement group_id="O2" value="3.49" lower_limit="2.50" upper_limit="5.80"/>
                    <measurement group_id="O3" value="3.33" lower_limit="2.44" upper_limit="5.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 5 (n=193, n=120, n=73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.39" lower_limit="2.08" upper_limit="5.71"/>
                    <measurement group_id="O2" value="3.53" lower_limit="2.08" upper_limit="5.48"/>
                    <measurement group_id="O3" value="3.33" lower_limit="2.35" upper_limit="5.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 6 (n=178, n=110, n=68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.41" lower_limit="2.13" upper_limit="5.71"/>
                    <measurement group_id="O2" value="3.61" lower_limit="2.13" upper_limit="5.48"/>
                    <measurement group_id="O3" value="3.33" lower_limit="2.35" upper_limit="5.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 7 (n=163, n=99, n=64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.53" lower_limit="2.13" upper_limit="5.71"/>
                    <measurement group_id="O2" value="3.70" lower_limit="2.13" upper_limit="5.66"/>
                    <measurement group_id="O3" value="3.33" lower_limit="2.56" upper_limit="5.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 8 (n=153, n=91, n=62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.53" lower_limit="2.13" upper_limit="5.71"/>
                    <measurement group_id="O2" value="3.70" lower_limit="2.13" upper_limit="5.56"/>
                    <measurement group_id="O3" value="3.33" lower_limit="2.50" upper_limit="5.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infusion 9 (n=143, n=83, n=60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.53" lower_limit="2.38" upper_limit="5.71"/>
                    <measurement group_id="O2" value="3.70" lower_limit="2.43" upper_limit="5.56"/>
                    <measurement group_id="O3" value="3.33" lower_limit="2.38" upper_limit="5.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Remicade Dose Per Participant</title>
        <time_frame>Maximum of 102 weeks</time_frame>
        <population>Remicade-naive participants who were exposed to Remicade during the observational study.</population>
        <group_list>
          <group group_id="O1">
            <title>Remicade (Specialized Hospitals &amp; Extramural Infusion Centers)</title>
            <description>Remicade induction therapy consisted of 3 infusions (3 mg/kg) in weeks 0, 2, and 6 given in specialized centers (specialized hospitals and extramural infusion centers). Maintenance therapy consisted of a maximum of 6 infusions (3 mg/kg) given in doses and intervals at the discretion of physician. The observation period could not exceed 102 weeks per participant if the maximal therapy interval of 16 weeks as defined in SPC was taken into consideration.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Remicade Dose Per Participant</title>
          <population>Remicade-naive participants who were exposed to Remicade during the observational study.</population>
          <units>mg/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.56" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Remicade Dose Per Participant</title>
        <time_frame>Maximum of 102 weeks</time_frame>
        <population>Remicade-naive participants who were exposed to Remicade during the observational study.</population>
        <group_list>
          <group group_id="O1">
            <title>Remicade (Specialized Hospitals &amp; Extramural Infusion Centers)</title>
            <description>Remicade induction therapy consisted of 3 infusions (3 mg/kg) in weeks 0, 2, and 6 given in specialized centers (specialized hospitals and extramural infusion centers). Maintenance therapy consisted of a maximum of 6 infusions (3 mg/kg) given in doses and intervals at the discretion of physician. The observation period could not exceed 102 weeks per participant if the maximal therapy interval of 16 weeks as defined in SPC was taken into consideration.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Remicade Dose Per Participant</title>
          <population>Remicade-naive participants who were exposed to Remicade during the observational study.</population>
          <units>mg/kg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.49" lower_limit="2.08" upper_limit="5.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impact of Remicade Location (Specialized Hospitals Versus Extramural Infusion Centers) on the Physical Component Summary Score (PCS)</title>
        <description>Participant's quality of life was measured by the short-form 36 (SF-36). The SF-36 is a survey with 36 questions. It is composed of the PCS &amp; the Mental Component Summary Score (MCS). The SF-36 consisted of eight scaled scores, which were the weighted sums of the questions in their section. Each scale was directly transformed into a 0 (lowest level of functioning) - 100 (highest level of functioning) scale on the assumption that each question carried equal weight. The impact of the maintenance therapy location (specialized hospitals versus extramural infusion centers) was also examined.</description>
        <time_frame>24 months maximum</time_frame>
        <population>Remicade-naive participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Remicade (Specialized Hospitals Only)</title>
            <description>Remicade induction therapy consisted of 3 infusions (3 mg/kg) in weeks 0, 2, and 6 given in specialized hospitals. Maintenance therapy consisted of a maximum of 6 infusions (3 mg/kg) given in doses and intervals at the discretion of physician. The observation period could not exceed 102 weeks per participant if the maximal therapy interval of 16 weeks as defined in SPC was taken into consideration.</description>
          </group>
          <group group_id="O2">
            <title>Remicade (Extramural Infusion Centers Only)</title>
            <description>Remicade induction therapy consisted of 3 infusions (3 mg/kg) in weeks 0, 2, and 6 given in extramural infusion centers. Maintenance therapy consisted of a maximum of 6 infusions (3 mg/kg) given in doses and intervals at the discretion of physician. The observation period could not exceed 102 weeks per participant if the maximal therapy interval of 16 weeks as defined in SPC was taken into consideration.</description>
          </group>
        </group_list>
        <measure>
          <title>Impact of Remicade Location (Specialized Hospitals Versus Extramural Infusion Centers) on the Physical Component Summary Score (PCS)</title>
          <description>Participant's quality of life was measured by the short-form 36 (SF-36). The SF-36 is a survey with 36 questions. It is composed of the PCS &amp; the Mental Component Summary Score (MCS). The SF-36 consisted of eight scaled scores, which were the weighted sums of the questions in their section. Each scale was directly transformed into a 0 (lowest level of functioning) - 100 (highest level of functioning) scale on the assumption that each question carried equal weight. The impact of the maintenance therapy location (specialized hospitals versus extramural infusion centers) was also examined.</description>
          <population>Remicade-naive participants with available data.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=194, n=121)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.25" spread="15.78"/>
                    <measurement group_id="O2" value="31.59" spread="16.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (after 9 infusions; n=125, n=13))</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.96" spread="22.26"/>
                    <measurement group_id="O2" value="42.46" spread="20.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impact of Remicade Location (Specialized Hospitals Versus Extramural Infusion Centers) on the MCS</title>
        <description>Participant's quality of life was measured by the short-form 36 (SF-36). The SF-36 is a survey with 36 questions. It is composed of the PCS &amp; the MCS. The SF-36 consisted of eight scaled scores, which were the weighted sums of the questions in their section. Each scale was directly transformed into a 0 (lowest level of functioning) - 100 (highest level of functioning) scale on the assumption that each question carried equal weight. The impact of the maintenance therapy location (specialized hospitals versus extramural infusion centers) was also examined.</description>
        <time_frame>24 months maximum</time_frame>
        <population>Remicade-naive participants with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Remicade (Specialized Hospitals Only)</title>
            <description>Remicade induction therapy consisted of 3 infusions (3 mg/kg) in weeks 0, 2, and 6 given in specialized hospitals. Maintenance therapy consisted of a maximum of 6 infusions (3 mg/kg) given in doses and intervals at the discretion of physician. The observation period could not exceed 102 weeks per participant if the maximal therapy interval of 16 weeks as defined in SPC was taken into consideration.</description>
          </group>
          <group group_id="O2">
            <title>Remicade (Extramural Infusion Centers Only)</title>
            <description>Remicade induction therapy consisted of 3 infusions (3 mg/kg) in weeks 0, 2, and 6 given in extramural infusion centers. Maintenance therapy consisted of a maximum of 6 infusions (3 mg/kg) given in doses and intervals at the discretion of physician. The observation period could not exceed 102 weeks per participant if the maximal therapy interval of 16 weeks as defined in SPC was taken into consideration.</description>
          </group>
        </group_list>
        <measure>
          <title>Impact of Remicade Location (Specialized Hospitals Versus Extramural Infusion Centers) on the MCS</title>
          <description>Participant's quality of life was measured by the short-form 36 (SF-36). The SF-36 is a survey with 36 questions. It is composed of the PCS &amp; the MCS. The SF-36 consisted of eight scaled scores, which were the weighted sums of the questions in their section. Each scale was directly transformed into a 0 (lowest level of functioning) - 100 (highest level of functioning) scale on the assumption that each question carried equal weight. The impact of the maintenance therapy location (specialized hospitals versus extramural infusion centers) was also examined.</description>
          <population>Remicade-naive participants with available data.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=194, n=124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.89" spread="17.98"/>
                    <measurement group_id="O2" value="45.12" spread="18.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (after 9 infusions; n=125, n=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.10" spread="20.96"/>
                    <measurement group_id="O2" value="46.18" spread="25.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Remicade (Specialized Hospitals &amp; Extramural Infusion Centers)</title>
          <description>Remicade induction therapy consisted of 3 infusions (3 mg/kg) in weeks 0, 2, and 6 given in specialized centers (specialized hospitals and extramural infusion centers). Maintenance therapy consisted of a maximum of 6 infusions (3 mg/kg) given in doses and intervals at the discretion of physician. The observation period could not exceed 102 weeks per participant if the maximal therapy interval of 16 weeks as defined in SPC was taken into consideration.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypochromic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Salivary gland adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Knee operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="516"/>
              </event>
              <event>
                <sub_title>Wrist surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="516"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

